{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-005970","form_type":"8-K","ticker":"SHPH","cik":"0001757499","company_name":"Shuttle Pharmaceuticals Holdings, Inc.","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.414964+00:00","generated_at":"2026-06-06T03:32:31.935435+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Shuttle Pharma to raise up to $4.5M via rights offering with SRO LLC backstop of $2.25M","bullets":["Rights offering of up to $4.5M units: 1 share SHPH + 1 warrant ($2.35 strike) + equity stake in Shuttle Diagnostics.","SRO LLC (affiliate of Boustead Securities CEO) commits $2.25M anchor purchase and backstop for unsold units up to additional $2.25M.","Unit price at 90% of 5-day VWAP; proceeds to fund diagnostics lab for clinical trials toward FDA device approval.","Boustead Securities receives $112,500 commitment fee, 8% commission on proceeds, plus $40,000 expenses.","Rights offering contingent on SEC registration statement filing (Form S-1) and effectiveness; timing uncertain."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-005970","json":"https://secwatch.observer/filing/0001493152-24-005970.json","markdown":"https://secwatch.observer/filing/0001493152-24-005970.md","text":"https://secwatch.observer/filing/0001493152-24-005970.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224005970/0001493152-24-005970-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224005970/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:32:31.935435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"190c6feaed51fb2541fc6d47d4dde46a96f2719f","claim":"Shuttle Pharmaceuticals Holdings, Inc. entered into Purchase Agreement with SRO, LLC valued at $2,250,000 (effective 2024-02-07).","evidence_excerpt":"Effective February 7, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“SHPH” or the “Company”), and its wholly-owned subsidiary, Shuttle Diagnostics, Inc., a Maryland corporation (“Diagnostics”), entered into a securities purchase agreement (the “Purchase Agreement”) with SRO, LLC, a Nevada limited liability company (“SRO LLC”), pursuant to which SRO LLC agreed to commit to purchasing from the Company $2,250,000 of units (the “Units”) from the Company","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224005970/0001493152-24-005970-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"SRO, LLC"},{"label":"Value","value":"$2,250,000"},{"label":"Effective","value":"2024-02-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}